Richard Shell

5.8k total citations · 2 hit papers
83 papers, 2.0k citations indexed

About

Richard Shell is a scholar working on Genetics, Molecular Biology and Pharmacology. According to data from OpenAlex, Richard Shell has authored 83 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Genetics, 26 papers in Molecular Biology and 14 papers in Pharmacology. Recurrent topics in Richard Shell's work include Neurogenetic and Muscular Disorders Research (25 papers), RNA modifications and cancer (14 papers) and Occupational Health and Safety Research (13 papers). Richard Shell is often cited by papers focused on Neurogenetic and Muscular Disorders Research (25 papers), RNA modifications and cancer (14 papers) and Occupational Health and Safety Research (13 papers). Richard Shell collaborates with scholars based in United States, France and United Kingdom. Richard Shell's co-authors include Linda Lowes, Lindsay N. Alfano, Kelly J. Lehman, Samiah Al-Zaidy, Jerry R. Mendell, Sam Salem, Nancy M. Daraiseh, Ash Genaidy, Kathleen Church and John T. Kissel and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Neurology.

In The Last Decade

Richard Shell

77 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy

2020 264 citations Jerry R. Mendell, Zarife Sahenk et al. profile →
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy

2021 173 citations Jerry R. Mendell, Samiah Al-Zaidy et al. profile →

Peers

Countries citing papers authored by Richard Shell

Since Specialization

Citations

This map shows the geographic impact of Richard Shell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Shell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Shell more than expected).

Fields of papers citing papers by Richard Shell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Shell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Shell. The network helps show where Richard Shell may publish in the future.

Co-authorship network of co-authors of Richard Shell

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Shell. A scholar is included among the top collaborators of Richard Shell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Shell. Richard Shell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial 2023 ·Muscle & Nerve ·Jerry R. Mendell, Zarife Sahenk, Kelly J. Lehman, Linda Lowes, Natalie F. Reash, M. Iammarino, Lindsay N. Alfano, Sarah Lewis, Kathleen Church, Richard Shell, Rachael A. Potter, Danielle A. Griffin, Mark Hogan, Shufang Wang, Stefanie Mason, (unknown), Louise R. Rodino‐Klapac	37
2	P314: Long-term safety and sustained functional benefit in patients with DMD 4 years post-treatment with delandistrogene moxeparvovec: A phase 1/2a study* 2023 ·SHILAP Revista de lepidopterología ·Erin O’Rourke, Jerry R. Mendell, Zarife Sahenk, Kelly J. Lehman, Linda Lowes, Natalie F. Reash, M. Iammarino, Lindsay N. Alfano, Sarah J. Lewis, Kathleen Church, Richard Shell, Rachael A. Potter, (unknown), Mark Hogan, Shufang Wang, Stefanie Mason, (unknown), Louise R. Rodino‐Klapac	1
3	Long-term Safety and Efficacy in Patients with DMD 4 Years Post-Treatment with Delandistrogene Moxeparvovec (SRP-9001) in a Phase 1/2a Study (P3-8.006) 2023 ·Neurology ·(unknown), Zarife Sahenk, Kelly J. Lehman, Linda Lowes, Natalie F. Reash, M. Iammarino, Lindsay N. Alfano, Sarah Lewis, Kathleen Church, Richard Shell, Rachael A. Potter, (unknown), Mark Hogan, Shufang Wang, Stefanie Mason, (unknown), Louise R. Rodino‐Klapac	2
4	Regional tree-ring oxygen isotope deduced summer monsoon drought variability for Kumaun-Gharwal Himalaya 2022 ·Quaternary Science Reviews ·Santosh K. Shah, Max Berkelhammer, Qiang Li, (unknown), (unknown), Richard Shell, (unknown), Narayan Prasad Gaire, Gayatri Kathayat, Ashish Sinha	6
5	Phase 1/2a Trial of SRP-9001 in Patients with Duchenne Muscular Dystrophy: 3-Year Safety and Functional Outcomes (S23.004) 2022 ·Neurology ·Jerry R. Mendell, Zarife Sahenk, Kelly J. Lehman, (unknown), Linda Lowes, Natalie F. Reash, M. Iammarino, Lindsay N. Alfano, (unknown), Sarah Lewis, Kathleen Church, Richard Shell, Rachael A. Potter, Danielle A. Griffin, Eric R. Pozsgai, Mark Hogan, (unknown), Kathryn Giblin, Louise R. Rodino‐Klapac	1
6	Protocol-driven early tracheal extubation in patients with flaccid neuromuscular scoliosis and pre-existing lung disease 2022 ·Spine Deformity ·(unknown), (unknown), (unknown), Joseph D. Tobias, David P. Martin, Richard Shell, (unknown), Allan Beebe, Walter Samora, (unknown)	1
7	EVALI versus MIS‐C, one more overlapping diagnosis to consider 2021 ·Pediatric Pulmonology ·(unknown), (unknown), (unknown), Richard Shell, (unknown), Brian Fowler, Rebecca Wallihan, Güliz Erdem	5
8	A 17-Year-Old With Becker Muscular Dystrophy and Unusual Polysomnography Findings 2021 ·CHEST Journal ·Grace Paul, Rami Khayat, Kavitha Kotha, Deipanjan Nandi, Linda Cripe, Richard Shell	0
9	AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort 2019 ·Journal of Neuromuscular Diseases ·Samiah Al-Zaidy, Stephen J. Kolb, Linda Lowes, Lindsay N. Alfano, Richard Shell, (unknown), Sukumar Nagendran, Douglas M. Sproule, Douglas E. Feltner, Courtney Wells, Francis G. Ogrinc, Melissa Menier, James L’Italien, W. David Arnold, John T. Kissel, Brian K. Kaspar, Jerry R. Mendell	128
10	SMA THERAPIES I 2018 ·Neuromuscular Disorders ·Richard Shell, (unknown), W. David Arnold, (unknown), T. Prior, (unknown), Grace Paul, Linda Lowes, Lindsay N. Alfano, Katherine Berry, (unknown), J. T. Kissel, (unknown), Francis G. Ogrinc, (unknown), Courtney Wells, Kathrin Meyer, Shibi Likhite, (unknown), (unknown)	2
11	AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Patients Treated Early with the Proposed Therapeutic Dose Were Able to Sit Unassisted at a Younger Age (S29.002) 2018 ·Neurology ·Lindsay N. Alfano, Linda Lowes, Samiah Al-Zaidy, Richard Shell, W. David Arnold, Louise R. Rodino‐Klapac, Thomas W. Prior, Katherine Berry, Kathleen Church, John T. Kissel, Sukumar Nagendran, James L’Italien, Douglas M. Sproule, Courtney Wells, Arthur H.M. Burghes, Kevin D. Foust, Kathrin Meyer, Shibi Likhite, Brian K. Kaspar, Jerry R. Mendell	1
12	Clinicopathologic Conference: A Newborn With Hypotonia, Cleft Palate, Micrognathia, and Bilateral Club Feet 2017 ·Pediatric Neurology ·Megan A. Waldrop, Daniel R. Boué, Emily Sites, Kevin M. Flanigan, Richard Shell	6
13	Cysteamine-mediated clearance of antibiotic-resistant pathogens in human cystic fibrosis macrophages 2017 ·PLoS ONE ·Chandra L. Shrestha, Kaivon Assani, (unknown), (unknown), Shuzhong Zhang, Richard Shell, Amal O. Amer, Larry S. Schlesinger, Benjamin T. Kopp	25
14	Breaking bad news is a teachable skill in pediatric residents: A feasibility study of an educational intervention 2015 ·Patient Education and Counseling ·Suzanne Reed, (unknown), Rollin Nagel, (unknown), John D. Mahan, Richard Shell	39
15	Applying Adult Learning Practices in Medical Education 2014 ·Current problems in pediatric and adolescent health care ·Suzanne Reed, Richard Shell, (unknown), (unknown), Rebecca Wallihan, (unknown), Larry Hurtubise, Bryan Martin, Cynthia H. Ledford, (unknown), Henry H. Bernstein, John D. Mahan	106
16	Neonatal Cyanosis Due to a Novel Fetal Hemoglobin: Hb F-Circleville [^Gγ63(E7)His→Leu, CAT>CTT] 2008 ·Hemoglobin ·(unknown), Richard Shell, Randy R. Miller, Joan Atkin, (unknown), Abdullah Kutlar, Lina Zhuang, (unknown), (unknown), F. Kutlar	16
17	Towards a Model of Safety Climate Measurement 2004 ·International Journal of Occupational Safety and Ergonomics ·Ali Al-Hemoud, (unknown), Richard Shell, Michael Gunn, (unknown)	9
18	Compression of the trachea by the innominate artery in a 2-month-old child 2001 ·Pediatric Pulmonology ·Richard Shell, Elizabeth D. Allen, Khaled H. Mutabagani, (unknown), J. Terrance Davis, Karen McCoy, Robert G. Castile	6
19	Chronic Aspiration Without Gastroesophageal Reflux as a Cause of Chronic Respiratory Symptoms in Neurologically Normal Infants 2001 ·CHEST Journal ·Shahid Sheikh, Elizabeth D. Allen, Richard Shell, (unknown), (unknown), Robert G. Castile, Karen McCoy	85
20	A Phase I Study of Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to a Lung Segment of Individuals with Cystic Fibrosis 1999 ·Human Gene Therapy ·Jonathan B. Zuckerman, Cynthia B. Robinson, (unknown), Richard Shell, Thomas J. Sferra, Narendra Chirmule, Susan Magosin, Kathleen J. Propert, (unknown), Joseph V. Hughes, John Tazelaar, Colleen Baker, Mitchell J. Goldman, James M. Wilson	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact